It is no secret that some growth stocks have been continuing to drive the market higher ever since the Great Recession ended almost 13 years ago. Record low lending rates have allowed fast-paced businesses to borrow cheaper capital, which they have used to acquire, hire and innovate.
But for some businesses, growth rates are just now kicking into high gear. This year, the following two stocks are some of the quickest growing businesses on the planet.
Novavax: 236% Estimated sales growth of
As has been the case for the last two years, pretty much everything that is tied to treatments for COVID has the potential to produce large revenue growth in 2022. According to the consensus prediction from Wall Street, the biotech stock Novavax is predicted to bring in around $4.62 billion in sales this year. This would mean a 236% increase over the $1.38 billion in forecasted sales for the year prior.
What has really helped to distance Novavax from the competition is Novavax’s vaccine efficacy (VE) for NVX-CoV2373. In two big-scale studies in the United Kingdom and Mexico/U.S., which were reported during March and June of this past year, Novavax’s COVID vaccine generated a VE of 89.7% and 90.4%. It is one of only three large vaccine businesses to have hit the 90% VE plateau.
What will be interesting to see is how fast Novavax will recover from the temporary falls it had 2021. These “falls” include the delay of the emergency-use authorization in many higher-dollar markets, as well as some concerns over vaccine purity and production. While these problems have now been resolved for the most part, they have significantly hurt Novavax’s stock value in recent months.
Also, Novavax has the potential of bringing an COVID-19/ influenza combination vaccine to the market quicker than many of its competitors. If this were to happen this year or early 2023, Novavax’s sales could skyrocket.
Vaxart: 1,644% Estimated sales growth of
If quadruple-digit sales growth is more your thing, you should take a look at clinical-stage biotech stock called Vaxart. If Wall Street’s predictions are correct, Vaxart will see a sales leap from just under $1 million in 2021 to about $17.3 million in 2022, representing a large increase of 1,644%.
What makes Vaxart so risky is the tech driving its research, as well as its main area of focus.
The company’s proprietary tech is known as “Vector-Adjuvant-Antigen Standardized Tech,” or VAAST. The VAAST platform was created to allow Vaxart to make oral therapies that treat ailments currently targeted by some vaccines. The advantage provided by VAAST is that it activates mucosal and systemic immunity within the lungs, nose, mouth and intestines in order to fight back against airborne viruses.
The hype that’s surrounding Vaxart is because it created a clinical-stage oral treatment for COVID. The business released a phase 1 study this past year that demonstrated a great immune response. However, its pill did not produce that same high-level effect of neutralizing antibodies that had been observed in vaccines.
This year, Vaxart is testing its own COVID-19 pill on a more specific protein and expecting better results. Though a lot is depending on the mid-stage study, even a mildly positive result could send the company’s revenue and shares soaring, with so many people still needing to get vaccinated worldwide.